Vimseltinib (DCC-3014)

Vimseltinib (DCC-3014) is a highly selective small-molecule inhibitor of colony-stimulating factor 1 receptor (CSF1R), with the molecular formula C₂₃H₂₅N₇O₂ and a molecular weight of 431.49 g/mol . It targets CSF1R, a receptor tyrosine kinase involved in the survival, proliferation, and differentiation of monocytes, macrophages, and osteoclasts.

By inhibiting CSF1R signaling, Vimseltinib interferes with macrophage-related pathways and modulates the tumor microenvironment (TME). This mechanism makes it a valuable compound for investigating tumor-associated macrophages (TAMs), immune regulation, and cancer-related signaling pathways.

Vimseltinib has been investigated in oncology research, particularly in tenosynovial giant cell tumor (TGCT), where CSF1R signaling plays an important role in disease progression. It is a useful research compound for studying CSF1R inhibition, macrophage biology, and potential targeted therapeutic strategies in oncology.